Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB)

Fei Li; Shou-Ching Tang

doi:10.1016/j.gendis.2017.01.004

Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB)

Genes Dis. 2017 Feb 10;4(1):1-3. doi: 10.1016/j.gendis.2017.01.004. eCollection 2017 Mar.

Authors

Fei Li^{1

2}, Shou-Ching Tang²

Affiliations

¹ The Editorial Office of Genes & Diseases, Chongqing, 400046, China.
² Georgia Cancer Center, Medical College of Georgia, Augusta University, GA, USA.

Abstract

We devoted this short interview piece with Dr Shou-Ching Tang at Augusta University to feature some promising results from a clinical phase II trial on a novel brain-penetrating peptide-paclitaxel-conjugate, ANG1005, in treating brain metastatic breast cancer. These results were presented by Dr. Tang at the recent annual meeting of the European Society for Medical Oncology (ESMO 2016 Congress). This development heralds an important step forward towards the development of effective chemotherapeutic agents, which can cross the blood-brain-barrier and effectively treat and prevent the brain metastatic cancers.

Keywords: ANG1005; Brain metastasis; Breast cancer; LRP-1; The blood-brain-barrier.

Publication types

Editorial